A groundbreaking discovery in the world of multiple sclerosis (MS) research has the potential to revolutionize our understanding of this complex disease. The power of genetics is about to unlock a new era in MS treatment and prevention.
Australian scientists, led by Dr. Hamish King at WEHI, have embarked on a project that aims to study over 100 genetic risk factors for MS simultaneously. This breakthrough initiative, funded by MS Australia's $2.8 million research grant, addresses a critical gap in our knowledge of MS genetics.
Over the years, extensive genetic studies have identified numerous small DNA changes associated with an increased risk of MS. However, most of these changes do not directly alter genes but instead influence how genes are activated or deactivated within immune cells. This complexity has made it challenging to comprehend their precise role in disease development.
But here's where it gets controversial: Dr. King's team is taking a bold step forward. They will introduce and test these genetic risk factors in human immune cells, measuring their individual and combined effects on gene activity and immune behavior. By doing so, they aim to unravel the intricate web of interactions between these risk factors and their impact on MS.
Dr. King emphasizes the potential impact of this research: "Understanding how networks of risk genes operate together could lead to more precise treatments and, ultimately, better long-term outcomes for individuals living with MS."
MS, an immune-mediated condition, occurs when the body mistakenly attacks the brain and spinal cord, damaging the protective myelin coating around nerve fibers. This can lead to various symptoms, including mobility issues, vision problems, cognitive impairments, and energy level fluctuations.
In Australia, the prevalence of MS is on the rise, with over 37,700 individuals affected in 2025, a 77.4% increase since 2010. The economic burden of the disease reached a staggering $3 billion in 2024.
As the numbers grow, the urgency to accelerate research across the entire spectrum of MS becomes evident. MS Australia's Head of Research, Dr. Tennille Luker, highlights the significance of projects like Dr. King's: "Identifying risk is just the first step. Understanding how genetic changes drive disease is crucial for changing its course."
In addition to Dr. King's project, MS Australia is investing in research that focuses on slowing disease progression, managing symptoms, and enhancing the quality of life for individuals with MS. These initiatives aim to strengthen our current response to MS while laying the scientific foundation for future prevention and cures.
The research grants will be officially launched at Parliament House in Canberra on March 4th, during MS Australia's Advancing MS Research in Australia event. Speakers, including Dr. Monique Ryan MP and Ms. Renee Coffey MP, will emphasize the importance of sustained national commitment to MS research.
Here are some of the featured projects:
Sensory Shoe Insoles for Improved Balance in MS: Associate Professor Anna Hatton from The University of Queensland is developing sensory shoe insoles to enhance foot sensation and improve balance in individuals with MS. The goal is to reduce the risk of falls, support mobility and independence, and boost everyday confidence.
Protecting Brain Blood Flow to Slow MS Progression: Professor Kaylene Young from the Menzies Institute for Medical Research, University of Tasmania, is investigating how changes in brain blood vessels may contribute to MS progression. Her team aims to identify drug targets that protect myelin and slow disability by examining genetic differences and their impact on blood flow and nerve cell survival.
Investigating the Role of Common Viruses in MS: Mr. Alex Eisner from The Florey Institute of Neuroscience and Mental Health, the University of Melbourne, is examining how Epstein-Barr virus and other common herpesviruses may influence MS. By studying associated antibody responses and epigenetic programming, Alex's project aims to clarify the molecular mechanisms underlying viral infections and their impact on MS risk, progression, and treatment response.
Exploring Copper Disruption as a Linking Factor in MS Risk: Dr. Brittney Lins from Curtin University is investigating whether disrupted copper levels in the brain connect major MS risk factors, including Epstein-Barr virus infection, vitamin D deficiency, and gut health. The project aims to identify new prevention and treatment strategies by examining the role of copper imbalance in myelin damage.
These projects showcase the diverse and innovative approaches being taken to tackle MS from various angles. By combining genetic insights, immune system research, and environmental factors, scientists are determined to unlock the mysteries of this debilitating disease.
As we await the outcomes of these groundbreaking studies, one thing is clear: the passion and dedication of researchers, donors, and the MS community are driving us closer to a world without MS. With sustained national investment and collaboration, we can continue to accelerate progress and bring hope to those affected by this condition.
